The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.
about
Of mice and men: novel insights regarding constitutive and recruitable brown adipocytesUnlock the Thermogenic Potential of Adipose Tissue: Pharmacological Modulation and Implications for Treatment of Diabetes and ObesityHypothalamic Obesity in Craniopharyngioma Patients: Disturbed Energy Homeostasis Related to Extent of Hypothalamic Damage and Its Implication for Obesity InterventionCombination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity.Cellular bioenergetics as a target for obesity therapy.Brown fat as a therapy for obesity and diabetes.Contributions of adipocyte lipid metabolism to body fat content and implications for the treatment of obesity.Pharmacological treatment of obesity in children and adolescents: present and futureAre there functional β₃-adrenoceptors in the human heart?Human atrial β(1L)-adrenoceptor but not β₃-adrenoceptor activation increases force and Ca(2+) current at physiological temperature.Translational issues in targeting brown adipose tissue thermogenesis for human obesity management.Current and future drug targets in weight managementAdipose tissue plasticity from WAT to BAT and in between.Npvf: Hypothalamic Biomarker of Ambient Temperature Independent of Nutritional StatusBrown adipose tissue: endocrine determinants of function and therapeutic manipulation as a novel treatment strategy for obesity.Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthaseCold but not sympathomimetics activates human brown adipose tissue in vivo.Challenges in β(3)-Adrenoceptor Agonist Drug DevelopmentHuman adipose dynamics and metabolic healthRelationship of brown adipose tissue perfusion and function: a study through β2-adrenoreceptor stimulation.Metabolic inflexibility of white and brown adipose tissues in abnormal fatty acid partitioning of type 2 diabetes.β(3)-Adrenoceptor ligand development history through patent review.A new era for brown adipose tissue: New insights into brown adipocyte function and differentiation.The search for compounds that stimulate thermogenesis in obesity management: from pharmaceuticals to functional food ingredients.Recruitment of brown adipose tissue as a therapy for obesity-associated diseases.Do we need anti-obesity drugs?Brown adipose tissue: development, metabolism and beyond.Plant-derived food ingredients for stimulation of energy expenditure.Dependence of β3-adrenergic signaling on the adipokine leptin in cardiac myocytes.Human brown adipose tissue as a target for obesity management; beyond cold-induced thermogenesis.Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat.Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors?Pharmacological Activation of Thyroid Hormone Receptors Elicits a Functional Conversion of White to Brown Fat.Antagonists of GPR35 display high species ortholog selectivity and varying modes of action.Targeting adipose tissue.Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges.The tertiary amine nitrogen atom of piperazine sulfonamides as a novel determinant of potent and selective beta3-adrenoceptor agonists.Steady-state energy balance in animal models of obesity and weight loss.Antilipolytic effects of 1,8-naphthyridine derivatives β-adrenoceptor antagonists in rat white adipocytes.The role of α1-adrenergic receptors in regulating metabolism: increased glucose tolerance, leptin secretion and lipid oxidation.
P2860
Q26751902-D016AD4D-2FAC-4B01-9F0D-B4FF2B7AD8DAQ26774736-AAE6D6E7-4B94-4A2B-99AE-F11C436A0A39Q26786921-74AF5D28-2553-4638-A42B-EDF89AFE6537Q33598749-E036D62B-FC33-47BF-B9E4-B00924EB7D2AQ33894407-8F29C60D-420F-484D-BF6C-336C6A665896Q34099153-C89DA479-53E6-438C-B423-C457E5D0D747Q34154607-8C5BFD5E-280C-4100-B07D-61A1FADF28D8Q34442880-A783F198-91BE-4704-B171-E1E51D35BF19Q34588651-7D775AEF-4893-4B31-A0E6-69FDBD16BEF5Q34588659-34078D0C-E947-4005-ACB3-365924DD6701Q34852201-B3A932F7-93A0-4A74-8F9B-C0C1C32F1F8DQ35089784-09CBD0CF-7382-4006-91A7-64BD246EF2ACQ35619414-FA9A34EB-04C8-4271-A454-B751AD53978AQ35662308-CB39A4FC-EEDD-495F-9472-D05BAF0DB7F4Q35943980-8E44D60D-FFBA-40E4-AF2F-088EF70EB1CEQ36006132-DE189352-D00D-4F51-BF89-FB8BC3E4F27FQ36056500-B908A422-6FA3-4C0E-A4C7-8CE8BAA05154Q36327996-0DEE2D5D-E448-49B8-8856-668DB70E1DF8Q36745558-24E282B8-AB4E-4B09-83DC-932B272E4386Q36810665-A57C1FAE-CC24-4EB9-8526-0AA042F35B6BQ36850836-413F02FB-0410-4CCC-994A-2F516C235A69Q37853580-20F48EF7-EC0D-479B-863A-B51937932B9BQ37856259-FF312FE4-63FB-454E-8A14-D58F094E1C5EQ37939346-6DAFC56C-21D9-4541-BD6F-A9508FA1DD9AQ38015370-95C2AC38-6D14-4AF3-B589-43CDF6188113Q38071006-99D12DAB-9B3D-45A8-B07F-34A2BEFD34BEQ38117395-310BAB6D-26C0-4962-ABA2-494003BB6270Q38159762-0ABE8147-9DA1-4F26-8E08-E0C69137CFEFQ38333286-4AD9F289-4FF9-4151-9967-CEF2268B4E9AQ39434608-EFC946A6-8376-4E27-96BB-9FA4F0643807Q39699981-743C4950-0774-4241-954E-E0FCC04D2145Q39897148-B74B5FD5-B1B0-4372-9333-62E823AF4B59Q40299694-8E9345C8-FEA2-49D7-9D27-66B2EB2E5E37Q41401817-2855177A-74D0-4C90-9E1C-DB03A9970559Q41891082-0DEA4B54-33D7-48EF-B9A9-B6646B0842BDQ42732323-303D418C-7425-488D-9F3F-8E2E46470CF1Q43250668-B153159E-71B6-4547-BD39-29F67DC50977Q47249526-D78BEFFA-6D5D-497F-86D3-A251042D64D1Q48093060-0D403BCA-7A90-4028-91DB-99AB886C97E0Q51283489-3C10D3A2-5E73-4B4F-8D0C-C772F408A22B
P2860
The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The discovery of drugs for obe ...... m beta3-adrenoceptor agonists.
@en
The discovery of drugs for obe ...... m beta3-adrenoceptor agonists.
@nl
type
label
The discovery of drugs for obe ...... m beta3-adrenoceptor agonists.
@en
The discovery of drugs for obe ...... m beta3-adrenoceptor agonists.
@nl
prefLabel
The discovery of drugs for obe ...... m beta3-adrenoceptor agonists.
@en
The discovery of drugs for obe ...... m beta3-adrenoceptor agonists.
@nl
P2860
P1476
The discovery of drugs for obe ...... m beta3-adrenoceptor agonists.
@en
P2093
Jonathan R S Arch
P2860
P2888
P304
P356
10.1007/S00210-008-0271-1
P577
2008-07-09T00:00:00Z